Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PROCEPT BioRobotics Corporation - Common Stock (NQ:PRCT)

35.36 -0.30 (-0.84%)
Streaming Delayed Price Updated: 11:52 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PROCEPT BioRobotics Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
How Is The Market Feeling About PROCEPT BioRobotics? ↗
 
Via Benzinga
News headline image
Spruce Point Sees Trouble Ahead For Procept BioRobotics ↗
Spruce Point Capital warns of Procept BioRobotics' overstated market potential and growth claims, citing niche product limitations and valuation risks. 
Via Benzinga
News headline image
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos ↗
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
News headline image
5 Analysts Assess PROCEPT BioRobotics: What You Need To Know ↗
 
Via Benzinga
News headline image
Looking Into PROCEPT BioRobotics's Recent Short Interest ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 6 Takes On PROCEPT BioRobotics ↗
 
Via Benzinga
News headline image
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
Via Benzinga
News headline image
PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
PROCEPT BioRobotics's Earnings Outlook ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About PROCEPT BioRobotics Stock ↗
 
Via Benzinga
News headline image
Royal Caribbean Sails Onto The IBD 50: Build Your List Of Stocks To Watch With These Top IBD Screens ↗
Royal Caribbean earns its spot on the Big Cap 20 with a best-possible 99 Composite Rating, putting it in the top 1% of all stocks. 
Via Investor's Business Daily
News headline image
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential ↗
PROCEPT BioRobotics stock gains as Q3 earnings beat estimates with revenue up 66% YoY, driven by strong system sales and consumable revenue growth. 
Via Benzinga
Topics Earnings
News headline image
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Navigating 6 Analyst Ratings For PROCEPT BioRobotics ↗
 
Via Benzinga
News headline image
Unveiling 4 Analyst Insights On PROCEPT BioRobotics ↗
 
Via Benzinga
News headline image
Procept Biorobotics, A Top 5% Stock, Makes A Bullish Move On Quarterly Beat And Raise ↗
The company sells systems that perform aquablation to treat enlarged prostates. 
Via Investor's Business Daily
News headline image
PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
Jim Cramer Says This Retailer Yields 3%: 'Which Is Quite Good' ↗
Jim Cramer discusses PROCEPT BioRobotics, Zoetis, Target and Consolidated Edison. " 
Via Benzinga
News headline image
PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio? ↗
 
Via Benzinga
News headline image
Nasdaq Gains 0.5%; TJX Earnings Top Estimates ↗
 
Via Benzinga
News headline image
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
Designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes 
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
3 Robotics Stocks to Sell in August Before They Crash & Burn ↗
Discover which robotics stocks to sell in August and why, ensuring you avoid potential market downturns and secure your investments. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.